Cell and Gene Outsourcing

  1. A Multi-Agent Audit Intelligence Framework For CDMO Quality Oversight 5/18/2026

    A Takeda quality executive demonstrates how a team of AI agents uses synthetic data to provide decision support ahead of CDMO audits.

  2. Why Contamination Control By Design Should Matter To Your CDMO 5/18/2026

    EU GMP Annex 1 mandates a documented contamination control strategy, and FDA expectations are substantively equivalent. Let's look at why CDMOs are disproportionately exposed.

  3. A Rapid, Scalable Lentiviral Vector Purification Platform 5/15/2026

    Integrated capture and polishing reduce upstream impurities, enabling high‑capacity polishing, strong lentiviral recovery, and scalable purity for downstream in vivo applications.

  4. Accelerated Yield Optimization Of Affinity Capture 5/15/2026

    High‑throughput affinity screening shows how buffer and pH optimization can boost AAV5 recovery, enabling faster, more reliable downstream process development for challenging serotypes.

  5. Scaling Complex Science With Flexibility And Reliability 5/15/2026

    Discover a global CDMO that provides flexible small molecule development, manufacturing, and analytical services to accelerate drug commercialization and improve efficiency.

  6. Addressing The Acetonitrile Supply By Implementing Strategies 5/15/2026

    Rising acetonitrile demand threatens supply chains; recovery and reuse methods using evaporation and crystallization produce high‑purity solvent, reducing costs, waste, and reliance on fresh supply.

  7. An Innovative, Modular Approach To Flexible Supply Chain Management 5/15/2026

    Learn how modular strategies, global coordination, and data-driven decisions help maintain continuity, compliance, and speed amid constant uncertainty.

  8. Understanding The Regulatory Landscape For Ophthalmic Drug Products 5/14/2026

    Learn how evolving ophthalmic regulations, contamination control strategies, and advanced packaging solutions can help support compliance, product quality, and patient safety.

  9. Becoming A Cornerstone Of A CDMO Strategy In Denmark 5/14/2026

    Take a look at how modular design, digitalized quality systems, and sustainability-focused infrastructure are reshaping manufacturing, enabling faster paths from development to commercial supply.

  10. Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not 5/14/2026

    Tokyo Institute of Technology. London Business School. ETH Zürich. What do these institutions – and a biotech based in Mulhouse, France – have in common? Matthieu de Kalbermatten, CEO of CellProthera. His international experience adds up to this: Build an internal quality (cGMP) organization; become the master of the processes you create for your therapy, before moving to external help; then select your CDMO carefully – maybe just prior to Phase III.